CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis

Journal of Neuroimmunology

Volumn 131, Issue 1-2, 2002, Pages 213-215

  Mäurer, Mathias ^a   Ponath, Anke ^a   Kruse, Niels ^a   Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cytotoxic T lymphocyte antigen 4; Genetic polymorphism; Multiple sclerosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; DISEASE PROGRESSION; EXONS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOCONJUGATES; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0036791281     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00275-8     Document Type: Article

References (12)

1. Dyment D.A., Steckley J.L., Willer C.J., Armstrong H., Sadovnick A.D., Risch N., Ebers G.C. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study. J. Neuroimmunol. 123(1-2):2002;193-198.
2. Fukazawa T., Yanagawa T., Kikuchi S., Yabe I., Sasaki H., Hamada T., Miyasaka K., Gomi K., Tashiro K. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J. Neurol. Sci. 171(1):1999;49-55.
3. Harbo H.F., Celius E.G., Vartdal F., Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens. 53(1):1999;106-110.
4. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J. Immunol. 165(11):2000;6606-6611.
5. Ligers A., Xu C., Saarinen S., Hillert J., Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J. Neuroimmunol. 97(1-2):1999;182-190.
6. Ligers A., Teleshova N., Masterman T., Huang W.X., Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2(3):2001;145-152.
7. Masterman T., Ligers A., Zhang Z., Hellgren D., Salter H., Anvret M., Hillert J. CTLA4 polymorphisms influence disease course in multiple sclerosis. J. Neuroimmunol. 131:2002;208-212.
8. Mäurer M., Kruse N., Giess R., Toyka K.V., Rieckmann P. Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J. Neuroimmunol. 104(1):2000;98-100.
9. Mäurer M., Loserth S., Kolb-Mäurer A., Ponath A., Wiese S., Kruse N., Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics. 54(1):2002;1-8.
10. Nijeholt G.J., van Walderveen M.A., Castelijns J.A., van Waesberghe J.H., Polman C., Scheltens P., Rosier P.F., Jongen P.J., Barkhof F. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 121(Pt. 4):1998;687-697.
11. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7(4):1997;445-450.
12. Thompson A.J., Montalban X., Barkhof F., Brochet B., Filippi M., Miller D.H., Polman C.H., Stevenson V.L., McDonald W.I. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 47(6):2000;831-835.